A recursive-partitioning model for blood-brain barrier permeation

Journal of Computer-Aided Molecular Design

Volumn 19, Issue 7, 2005, Pages 465-481

  Mente, Scot R ^a   Lombardo, F ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

ADME; Blood brain barrier; CNS; In silico; QSAR

Indexed keywords

BLOOD; COMPUTATIONAL CHEMISTRY; GLYCOPROTEINS; REGRESSION ANALYSIS;

ADME; BLOOD-BRAIN BARRIER; CHEMICAL SPACE; CNS; DESCRIPTORS; IN-SILICO; LOWER CORRELATION; P-GLYCOPROTEIN; QSAR; RECURSIVE PARTITIONING MODEL;

EXTRAPOLATION;

ACETYLSALICYLIC ACID; AMPRENAVIR; CENTRAL NERVOUS SYSTEM AGENTS; CLONIDINE; CODEINE; DIDANOSINE; FEXOFENADINE; FLUOXETINE; FLUVOXAMINE; GLYCOPROTEIN P; HEXOBARBITAL; IBUPROFEN; INDINAVIR; LOPERAMIDE; NELFINAVIR; NEVIRAPINE; OMEPRAZOLE; PARACETAMOL; PHENAZONE; PROPYLHEXEDRINE; QUINIDINE; SALICYLIC ACID; SERTRALINE; TERBINAFINE; TERFENADINE; THIOPENTAL; UNINDEXED DRUG; VALPROIC ACID; ZALCITABINE; ZIDOVUDINE;

ARTICLE; BLOOD BRAIN BARRIER; COMPUTER MODEL; CORRELATION COEFFICIENT; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; HYDROPHOBICITY; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; STATISTICAL ANALYSIS; STATISTICAL MODEL;

EID: 31444431893     PISSN: 0920654X     EISSN: 15734951     Source Type: Journal    
DOI: 10.1007/s10822-005-9001-7     Document Type: Article

References (123)

1. Young R.C., et al., (1988) J. Med. Chem. 31: 656
2. Abraham M.H., Chadha H., Mitchell R.C., (1994) J. Pharm. Sci. 83: 1257
3. Lombardo F., Blake J.F., Curatolo W.J., (1996) J. Med. Chem. 39: 4750
4. Platts J.A., et al., (2001) Eur. J. Med. Chem. 36: 719
5. Clark D.E., (1999) J. Pharm. Sci. 88: 815
6. Kelder J., et al., (1999) Pharma. Res. 16: 1514
7. Iyer M., et al., (2002) Pharma. Res. 19: 1611
8. Doniger S., Hofmann T., Yeh J., (2002) J. Comp. Bio. 9: 849
9. van de Waterbeemd H., Kansy M., (1992) Chimia. 46: 299
10. Chadha H., Abraham M.H., Mitchell R.C., (1994) Bio. Med. Chem. Lett. 4: 2511
11. Sippl W., (2002) Curr. Med. Chem.: Central Nervous Syst. Agents. 2: 211
12. Atkinson F., et al., (2002) Curr. Med. Chem.: Central Nervous Syst. Agents. 2: 229
13. Penzotti J.E., Landrum G.A., Putta S., (2004) Curr. Opinion Drug Discovery Dev. 7: 49
14. Lipinski, C.A., In Spellmeyer D.C., (Ed.), Annual Reports in Computational Chemistry, Elsevier: Amsterdam, pp. 155-168
15. Norinder U., Sjoberg P., Osterberg T., (1998) J. Pharm. Sci. 87:952
16. Osterber T., Norinder U., (2001) Eur. J. Pharm. Sci. 12: 327
17. Luco J.M., (1999) J. Chem. Inf. Comput. Sci. 39: 396
18. Rose K., Hall L.H., Kier L.B., (2002) J. Chem. Inf. Comput. Sci. 42: 651
19. Ajay G.W., Bemis, Murcko M.A., (1999) J. Med. Chem. 42: 4942
20. Crivori P., et al., (2000) J. Med. Chem. 43: 2204
21. Adenot M., Lahana R., (2004) J. Chem. Inf. Comput. Sci. 44: 239
22. Maclin R., Opitz D., (1999) J. Art. Intelligence Res. 11: 169
23. Stanton D.T., Jurs P., (1990) Jurs C., Anal. Chem. 62: 2323
24. Lipinski C.A., et al., (1997) Adv. Drug Del. Rev. 23: 3
25. Labute P., (2000) J. Mol. Graphics Model. 18: 464
26. Cruciani G., et al., (2000) J. Mol. Struct.: THEOCHEM.503: 17
27. Cruciani, G., Pastor, M. and Clementi, S., In: Gundertofte, K. and Jorgensen, F.E., (Eds.), Molecular Modeling and Prediction of Bioactivity, Kluwer Academic/Plenum Publishers: New York, 2000, 73pp
28. Maw H.H., Hall L.H., (2000) J. Chem. Inf. Comput. Sci. 40: 1270
29. Kimberly R., Hall L.H., (2002) J. Chem. Inf. Comput. Sci. 42: 651
30. Gasteiger J., Rudolph C., (1990) J. Sadowski, Tetrahedron Comp. Method. 3: 537
31. G.D. Hawkins 2003 AMSOL University of Minnesota Minneapolis
32. Hawkins G.D., Cramer C.J., Truhlar D.G., (1996) J. Phys. Chem. 100: 19824
33. Chambers C.C., et al., (1996) J. Phys. Chem. 100: 16385
34. Pearlman, R.S., In Valvani S.C. (Ed.), Physical Chemical Properties of Drugs, Marcel Dekker: New York, 1980
35. Andrews P.R., Craik D.J., Martin J.L., (1984) J. Med. Chem. 27: 1648
36. BioByte, CLOGP. 2005, BioByte Corp: Claremont, CA
37. Ertle P., Rohde B., Selter P., (2000) J. Med. Chem. 43: 3714
38. Moriguchi I., et al., (1992) Chem. Pharmacol. Bull. 40: 127
39. Chemical Computing Group Inc, C. 2000 Molecular Operating Environment Chemical Computing Group Inc Montreal
40. Gasteiger J., Marsili M., (1980) Tetrahedron, 36: 3219
41. Kalvass J.C., Maurer T.S., (2002) Biopharma. Drug Disposition, 23: 327
42. Waterbeemd, H.v.d., Smith D.A., Jones B.C., (2001) J. Comp.-Aided Mol. Design. 15: 273
43. Brejc K., et al., (2001) Nature 411: 269
44. Iven H., Feldbusch E., (1983) Naunyn-Schmiedeberg's Arch Pharmacol. 324: 153
45. Timmermans P.B.M.W.M., Brands A., Van Zwieten A., (1977) Arch. Pharmacol. 300: 217
46. Cvetkovic M., et al., (1999) Drug Metabol. Dispos. 27: 866
47. de Lange E.C.M., et al., (1994) Brain Research, 666: 1
48. Miyagi N., et al., (1986) J. Pharmacobio-Dynamics 9: 704
49. Rizk M., Curro F.A., Abdel-Rahman M.S., (1995) Pharmacol. Commun. 6: 295
50. Bickel M., Gerny R., (1980) J. Pharmacy Pharmacol. 32: 669
51. Dambisya Y.M., Chan K., Wong C.-L., (1992) J. Pharmacy Pharmacol. 44: 687-690
52. Cox D.S., et al., (2001) J. Pharm. Sci. 90: 1540
53. Chou R.C., Levy G., (1981) J. Pharm. Exp. Therapeutics 219: 42
54. Kunsman G.W., Rohrig T.P., (1993) Am. J. Forensic Med. Pathol. 14: 48
55. Yata N., et al., (1990) Pharma. Res. 7: 1019
56. Vajda F.J.E., et al., (1981) Neurology 31: 486
57. Bolo N.R., et al., (2000) Neuropsychopharmacology 23: 428
58. Lefebvre M., et al., (1999) Life Sci. 64: 805
59. Hosseini-Yeganeh M., Mclachlan A.J., (2001) J. Pharm. Sci. 90: 1817
60. Cheng F.C., et al., (2002) J. Chromatography, A. 949: 35
61. Borg N., Stahle L., (1998) Antimicrob. Agents Chemother. 42: 2174
62. Ibrahim S.S., et al., (1996) Antivirial Chem. Chemother. 7: 167
63. Choo E.F., et al., (2000) Drug Metabolism Disposition 28: 655
64. Anderson B.D., et al., (1990) J. Pharm. Exp. Therapeutics 253: 113
65. Glynn S.L., Yazdanian M., (1998) J. Pharm. Sci. 87: 306
66. Bolander H.G., Wahlstrom G., (1984) Neuropharmacology 23: 977
67. Bolander H.G., Wahlstrom G., Norberg L., (1984) Acta. Phar. et. Tox. 54: 33
68. Lin Y.-J., et al., (1973) Chem. Pharmacol. Bull. 21: 2749
69. Arendt R.M., et al., (1987) Psychopharmacology 93: 72
70. Mandema J., Kuck W.M.T., Danhof M., (1992) Br. J. Pharmacol. 105: 164
71. Scavone J.M., et al., (1987) Arzneim.-Forsch. 37: 2
72. Lin J.H., Chen I.-W., Lin T.-H., (1994) J. Pharm. Exp. Therapeutics 271: 1197
73. R.C. Baselt 2002 Disposition of Toxic Drugs and Chemicals in Man 6 Chemical Toxicology Institute Foster City, CA
74. Cruickshank J.M., et al., (1980) Clin. Sci. 59: 453s
75. Arendt R.M., et al., (1984) Cardiology 71: 307
76. Matsui K., et al., (1999) Drug Metabol. Disposition 27: 1406
77. Kewitz H., (1997) Drugs Today 33: 265
78. Kosasa T., et al., (2000) Eur. J. Pharmacol. 389: 173
79. Vezzani A., et al., (1989) J. Pharm. Exp. Therapeutics, 249: 278
80. Kuroda S., et al., (2001) Chem. Pharmacol. Bull. 49: 988
81. Calder J.A.D., Ganellin C.R., (1994) Drug Design Discovery 11: 259
82. Polli J.W., et al., (2003) J. Pharm. Sci. 92: 2082
83. Pong S.F., Huang C.L., (1974) J. Pharm. Sci. 63: 1527
84. Brown E.A., et al., (1986) Br. J. Pharmacol. 87:569
85. Barkai A.I., Suckow R.F., Cooper T.B., (1984) J. Pharm. Exp. Therapeutics. 230: 330
86. Doran A., et al., (2005) Drug Metabol. Disposition 33:165
87. Hirose H., et al., (2001) J. Pharm. Exp. Therapeutics 297:790
88. Schmalzing G., (1977) Drug Metabol. Disposition 5: 104
89. Tsuneizumi T., Babb S.M., Cohen B.M., (1992) Biol. Psychiatr. 32: 817
90. Sunderland T., Cohen B.M., (1987) Psychiatr. Res. 20: 299
91. Hu O.Y.-P., Curry S.H., (1989) Biopharma. Drug Disposition 10: 537
92. Yeleswaram K., et al., (1995) Res. Comm. Mol. Pathology Pharmacol. 89: 27
93. Scales B., Cosgrove M.B., (1970) J. Pharm. Exp. Therapeutics 175: 338
94. Riah O., et al., (1998) Cell. Mol. Neurobiol. 18: 311
95. Ghosheh O.A., et al., (2001) Drug Metabol. Disposition 29: 645
96. Romano C., Goldstein A., Jewell N.P., (1981) Psychopharmacology 74: 310
97. Rowell P.P., Li M.,. (1997) J. Neurochem. 68: 1982
98. Schroeder D.H., (1983) J. Clin. Psychiatr. 44: 79
99. Kaplan G.B., et al., (1989) J. Pharm. Exp. Therapeutics 248: 1078
100. Wilkinson J.M., Pollard I., (1993) Dev. Brain Res. 75: 193
101. Terasaki T., et al., (1992) Int. J. Pharmaceutics 81: 143
102. Stahle L., (1991) Life Sci. 49: 1835
103. Ramzan I.M., Levy G., (1986) J. Pharm. Exp. Therapeutics 236: 708
104. Ohshima N., et al., (1995) Biol. Pharma. Bull. 18: 70
105. Argent D., D'Mello A.P., (1994) J. Pharm. Exp. Therapeutics 270: 512
106. Okuyama S., Aihara H., (1984) Jpn. J. Pharmacol. 35: 95
107. Van Belle K., et al., (1995) J. Pharm. Exp. Therapeutics 272: 1217
108. Overo K.F., Jorgensen A., Hansen V., (1970) Acta. Phar. et. Tox. 28: 81
109. Yang H., Wang Q., Elmquist W.F., (1996) Pharma. Res. 13: 1570
110. Von Moltke L.L., et al., (2004) Drug Metab. Disposition 32: 800
111. Aravagiri M., Yuwiler A., Marder S.R., (1998) Psychopharmacology 139: 356
112. Yang Z., et al., (1997) Pharma. Res. 14: 865
113. McNally W., et al., (1989) Pharma. Res. 6: 924
114. Pan W.-J., Hedaya M.A., (1999) J. Pharm. Sci. 88: 468
115. Brogden, R.N., et al., Drugs, 24 (1982) 360
116. Lobell M., Molnar L., Keseru G.M., (2002) J. Pharm. Sci. 92: 360
117. Hou T., Xu X., (2002) J. Mol. Model, 8: 337
118. Keseru G.M., Molnar L., (2001) J. Chem. Inf. Comput. Sci. 41: 120
119. Bennet B., et al., (2000) J. Biol. Chem. 275: 20647
120. Shearman M.S., et al., (2000) Biochemistry 39: 8698
121. Jakovljevic V., Banic B., Radunovic A., (1991) Eur. J. Drug. Met. Pharmacokinetics 16:171
122. Reavill C., et al., (1990) Neuropharmacology 29: 619
123. Pentel P.R., et al., (2000) Pharmacol. Biochem. Behavior 65: 191